Cited by 109Rheumatoid Arthritis Research and TherapiesBiomarkers in Disease MechanismsSystemic Lupus Erythematosus Research

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Mechanistic biomarkers for clinical decision making in rheumatic diseases

Open access

Robinson, William H., Lindstrom, Tamsin M., Cheung, Regina K., Sokolove, Jeremy·2013·Nature Reviews Rheumatology

DOI 10.1038/nrrheum.2013.14PMC PMC3673766

Open this paper in CoChat — free account

Abstract

The use of biomarkers is becoming increasingly intrinsic to the practice of medicine and holds great promise for transforming the practice of rheumatology. Biomarkers have the potential to aid clinical diagnosis when symptoms are present or to provide a means of detecting early signs of disease when they are not. Some biomarkers can serve as early surrogates of eventual clinical outcomes or guide therapeutic decision making by enabling identification of individuals likely to respond to a specific therapy. Using biomarkers might reduce the costs of drug development by enabling individuals most likely to respond to be enrolled in clinical trials, thereby minimizing the number of participants required. In this Review, we discuss the current use and the potential of biomarkers in rheumatology and in select fields at the forefront of biomarker research. We emphasize the value of different types of biomarkers, addressing the concept of 'actionable' biomarkers, which can be used to guide clinical decision making, and 'mechanistic' biomarkers, a subtype of actionable biomarker that is embedded in disease pathogenesis and, therefore, represents a potentially superior biomarker. We provide examples of actionable and mechanistic biomarkers currently available, and discuss how development of such biomarkers could revolutionize clinical practice and drug development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrrheum.2013.14

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Systemic Lupus Erythematosus
Tsokos, G. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
What we can do and what we cannot do with fMRI
Logothetis, N. K. (2008) · Nature · doi:10.1038/nature06976 · Cited by 3,612
Systematic review and meta-analysis
Gillies, A. (2019) · CRC Press eBooks · doi:10.1201/9781315377315-19 · Cited by 2,876
Systemic Lupus Erythematosus
Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,814
Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021933 · Cited by 2,581
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis
Rantapää‐Dahlqvist, S., Jong, B. A. W. D., Berglin, E. H., Hallmans, G., Wadell, G., Stenlund, H. C., Sundin, U., & VENROOIJ, W. J. V. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11223 · Cited by 1,946
Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors
Nielen, M. M. J., van Schaardenburg, D., Reesink, H. W., van de Stadt, R. J., van der Horst-Bruinsma, I. E., Koning, M. H. M. T. D., Habibuw, M. R., Vandenbroucke, J. P., & Dijkmans, B. A. C. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20018 · Cited by 1,856
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
Biomarkers in Cancer Staging, Prognosis and Treatment Selection
Ludwig, J. A., & Weinstein, J. N. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1739 · Cited by 1,682
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Cohen, S. B., Emery, P., Greenwald, M., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., LOVELESS, J. E., Burmester, G. R., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis
PETERFY, C. G., Guermazi, A., Zaïm, S., Tirman, P. F. J., Miaux, Y., White, D. L., Kothari, M., Lü, Y., Fye, K. H., Zhao, S., et al. (2003) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2003.11.003 · Cited by 1,542
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R., Li, N. F., Agarwal, S. K., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,061
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival
Chang, H. Y., Nuyten, D. S. A., Sneddon, J. B., Hastie, T., Tibshirani, R., Sørlie, T., Dai, H., He, Y. D., van't Veer, L. J., Bartelink, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409462102 · Cited by 981
The Disease Activity Score and the EULAR Response Criteria
Fransen, J., & van Riel, P. L. C. M. (2009) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2009.10.001 · Cited by 966
Type I Interferon in Systemic Lupus Erythematosus and Other Autoimmune Diseases
Banchereau, J., & Pascual, V. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.010 · Cited by 955
Immune Interferon in the Circulation of Patients with Autoimmune Disease
Hooks, J. J., Moutsopoulos, H. Μ., Geis, S. A., Stahl, N. I., Decker, J. L., & Notkins, A. L. (1979) · New England Journal of Medicine · doi:10.1056/nejm197907053010102 · Cited by 921
IL-1 pathways in inflammation and human diseases
Gabay, C., Lamacchia, C., & Palmer, G. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.4 · Cited by 897
MicroRNA-155 Promotes Autoimmune Inflammation by Enhancing Inflammatory T Cell Development
O'Connell, R. M., Kahn, D., Gibson, W. S. J., Round, J. L., Scholz, R. L., Chaudhuri, A. A., Kahn, M. E., Rao, D. S., & Baltimore, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.009 · Cited by 889
Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9
Means, T. K., Latz, E., Hayashi, F., Murali, M. R., Golenbock, D. T., & Luster, A. D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23025 · Cited by 866
Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies
Verge, C. F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., Chase, H. P., Eisenbarth, G. S., & Jackson, R. A. (1996) · Diabetes · doi:10.2337/diab.45.7.926 · Cited by 827
Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients
Pauley, K. M., Satoh, M., Chan, A. L., Bubb, M., Reeves, W. H., & Chan, E. K. L. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2493 · Cited by 770
MicroRNA‐146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins
Tang, Y., Luo, X., Cui, H., Xu-ming, N., Yuan, M., Guo, Y., Huang, X., Zhou, H., de Vries, N., Tak, P. P., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24436 · Cited by 747
Expression of microRNA‐146 in rheumatoid arthritis synovial tissue
Nakasa, T., Miyaki, S., Okubo, A., Hashimoto, M., Nishida, K., Ochi, M., & Asahara, H. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23429 · Cited by 681
Lymphoid Neogenesis in Rheumatoid Synovitis
Takemura, S., Braun, A. B., Crowson, C. S., Kurtin, P. J., Cofield, R. H., O’Fallon, W. M., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.2.1072 · Cited by 651
Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study.
Ziegler, A., Hummel, M., Schenker, M., & Bonifacio, E. E. (1999) · Diabetes · doi:10.2337/diabetes.48.3.460 · Cited by 640
Phase II failures: 2008–2010
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event
Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., & Reindl, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022328 · Cited by 617
The double-blind, randomized, placebo-controlled trial
Kaptchuk, T. J. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00347-4 · Cited by 595
T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis
Axtell, R. C., de Jong, B. A., Boniface, K., van der Voort, L. F., Bhat, R., Sarno, P. D., Naves, R. F., Han, M. H., Zhong, F. L., Castellanos, J. G., et al. (2010) · Nature Medicine · doi:10.1038/nm.2110 · Cited by 546
Immunogenicity of protein therapeutics
Groot, A. S. D., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 544
Toll-like Receptor 9–Dependent and –Independent Dendritic Cell Activation by Chromatin–Immunoglobulin G Complexes
Uccellini, M. B., Broughton, C., Mackay, F., Akira, S., Marshak‐Rothstein, A., & Rifkin, I. R. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031942 · Cited by 528
Autoantibody Epitope Spreading in the Pre-Clinical Phase Predicts Progression to Rheumatoid Arthritis
Sokolove, J. B., Bromberg, R., Deane, K. D., Lahey, L. J., Derber, L. A., Chandra, P. E., Edison, J. D., Gilliland, W. R., Tibshirani, R. J., Norris, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035296 · Cited by 515
Self-citation
Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers
Trusheim, M. R., Berndt, E. R., & Douglas, F. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2251 · Cited by 510
Key factors in the rising cost of new drug discovery and development
Dickson, M., & Gagnon, J. P. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1382 · Cited by 507
The reliability of a new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion assessment: BLOKS (Boston–Leeds Osteoarthritis Knee Score)
Hunter, D. J., Lo, G. H., Gale, D. R., Grainger, A. J., Guermazi, A., & Conaghan, P. G. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066183 · Cited by 499
Phase III and submission failures: 2007–2010
Arrowsmith, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3375 · Cited by 480
Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis
Haringman, J. J., Gerlag, D. M., Zwinderman, A. H., Smeets, T. J. M., Kraan, M. C., Baeten, D., McInnes, I. B., Bresnihan, B., & Tak, P. P. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.029751 · Cited by 457
Up‐regulation of cytokines and chemokines predates the onset of rheumatoid arthritis
Kokkonen, H., Söderström, I., Rocklöv, J., Hallmans, G., Lejon, K., & Rantapää‐Dahlqvist, S. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27186 · Cited by 453
The FDA Critical Path Initiative and Its Influence on New Drug Development
Woodcock, J., & Woosley, R. L. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.090506.155819 · Cited by 435
High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus
Niewold, T. B., Hua, J., Lehman, T. J. A., Harley, J. B., & Crow, M. K. (2007) · Genes and Immunity · doi:10.1038/sj.gene.6364408 · Cited by 417
Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trial
van Dongen, H., van Aken, J., Lard, L. R., Visser, K., Ronday, H. K., Hulsmans, H. M. J., Speyer, I., Westedt, M. L., Peeters, A. J., Allaart, C. F., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22525 · Cited by 413
Apoptosis as a therapeutic tool in rheumatoid arthritis
Pope, R. M. (2002) · Nature reviews. Immunology · doi:10.1038/nri846 · Cited by 398
Immunologically Active Autoantigens: The Role of Toll-Like Receptors in the Development of Chronic Inflammatory Disease
Marshak‐Rothstein, A., & Rifkin, I. R. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104514 · Cited by 394
Activation of the type I interferon system in primary Sjögren's syndrome: A possible etiopathogenic mechanism
Båve, U., Nordmark, G., Lövgren, T., Rönnelid, J., Cajander, S. B., Eloranta, M., Alm, G. V., & Rönnblom, L. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20998 · Cited by 387
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 386
The pattern of response to anti–interleukin‐1 treatment distinguishes two subsets of patients with systemic‐onset juvenile idiopathic arthritis
Gattorno, M., Piccini, A., Lasigliè, D., Tassi, S., Brisca, G., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., Caroli, F., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23437 · Cited by 379
Genomics and the Multifactorial Nature of Human Autoimmune Disease
Cho, J. H., & Gregersen, P. K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100030 · Cited by 360
Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll‐like receptor 4 and Fcγ receptor
Sokolove, J. B., Zhao, X., Chandra, P. E., & Robinson, W. H. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30081 · Cited by 342
Self-citation
A macrophage marker, siglec‐1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll‐like receptor agonists
York, M. R., Nagai, T., Mangini, A. J., Lemaire, R., van Seventer, J. M., & Lafyatis, R. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22382 · Cited by 327
Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti–RNA binding protein autoantibodies
Hua, J., Kirou, K. A., Lee, C. L. L., & Crow, M. K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21890 · Cited by 317
Type I interferon–inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis
Walsh, R. J., Kong, S. W., Yao, Y., Jallal, B., Kiener, P. A., Pinkus, J. L., Beggs, A. H., Amato, A. A., & Greenberg, S. A. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22928 · Cited by 312
ANCA Are Detectable in Nearly All Patients with Active Severe Wegener’s Granulomatosis
Finkielman, J. D., Lee, A. S., Hummel, A. M., Viss, M. A., Jacob, G. L., Homburger, H. A., Peikert, T., Hoffman, G. S., Merkel, P. A., Spiera, R., et al. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.016 · Cited by 289
Neutralization of interferon‐α/β–inducible genes and downstream effect in a phase I trial of an anti–interferon‐α monoclonal antibody in systemic lupus erythematosus
Yao, Y., Richman, L. K., Higgs, B. W., Morehouse, C. A., Reyes, M. D. L., Brohawn, P. Z., Zhang, J., White, B., Coyle, A. J., Kiener, P. A., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24557 · Cited by 284
U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7
Savarese, E., Chae, O.-W., Trowitzsch, S., Weber, G., Kastner, B., Akira, S., Wagner, H., Schmid, R. M., Bauer, S., & Krug, A. (2005) · Blood · doi:10.1182/blood-2005-07-2650 · Cited by 273
An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes
Curtale, G., Citarella, F., Carissimi, C., Goldoni, M., Carucci, N., Fulci, V., Franceschini, D., Meloni, F., Barnaba, V., & Macino, G. (2010) · Blood · doi:10.1182/blood-2009-06-225987 · Cited by 263
Essential role of microRNA‐155 in the pathogenesis of autoimmune arthritis in mice
Blüml, S., Bonelli, M. M., Niederreiter, B., Puchner, A., Mayr, G., Hayer, S., Koenders, M. I., van den Berg, W. B., Smolen, J. S., & Redlich, K. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30281 · Cited by 260
The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age‐dependent manner
Deane, K. D., O’Donnell, C. I., Hueber, W., Majka, D. S., Lazar, A. A., Derber, L. A., Gilliland, W. R., Edison, J. D., Norris, J. M., Robinson, W. H., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27638 · Cited by 257
Self-citation
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis
Robinson, W. H., da Fontoura, P. P., Lee, B. J., de Vegvar, H. E. N., Tom, J. A., Pedotti, R., DiGennaro, C., Mitchell, D. J., Fong, D., Ho, P. P.-K., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt859 · Cited by 236
Self-citation
MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients
Niimoto, T., Nakasa, T., Ishikawa, M., Okuhara, A., Izumi, B., Deie, M., Suzuki, O., Adachi, N., & Ochi, M. (2010) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-11-209 · Cited by 235
Gene–environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis
Karlson, E. W., Chang, S.-C., Cui, J., Chibnik, L. B., Fraser, P. A., Vivo, I. D., & Costenbader, K. H. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.102962 · Cited by 232
MicroRNAs as biomarkers in rheumatic diseases
Alevizos, I., & Illei, G. G. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.81 · Cited by 231
Induction of interferon‐α by immune complexes or liposomes containing systemic lupus erythematosus autoantigen– and Sjögren's syndrome autoantigen–associated RNA
Lövgren, T., Eloranta, M., Kastner, B., Wahren‐Herlenius, M., Alm, G. V., & Rönnblom, L. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21893 · Cited by 231
Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade
Allantaz, F., Chaussabel, D., Stichweh, D., Bennett, L. B., Allman, W., Mejías, A., Ardura, M. I., Chung, W. K., Smith, E. J., Wise, C. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070070 · Cited by 228
Assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: the MOST study
Guermazi, A., Roemer, F. W., Hayashi, D., Crema, M. D., Niu, J., Zhang, Y., Marra, M. D., Katur, A. M., Lynch, J. A., el-Khoury, G. Y., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.139618 · Cited by 214
Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase
van de Sande, M. G. H., de Hair, M. J. H., van der Leij, C., Klarenbeek, P. L., Bos, W. H., Smith, M., Maas, M. M., de Vries, N., van Schaardenburg, D., Dijkmans, B. A. C., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.139527 · Cited by 212
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
Garren, H., Robinson, W. H., Krasulová, E., Havrdová, E., Nadj, Č., Selmaj, K. W., Losy, J., Nadj, I., Radue, E. W., Kidd, B. A., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21370 · Cited by 180
Self-citation
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study
Klarenbeek, N. B., Güler-Yüksel, M., van der Kooij, S. M., Han, K. H., Ronday, H. K., Kerstens, P. J. S. M., Seys, P. E. H., Huizinga, T. W. J., Dijkmans, B. A. C., & Allaart, C. F. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.141234 · Cited by 180
Increased levels of C‐reactive protein in serum from blood donors before the onset of rheumatoid arthritis
Nielen, M. M. J., van Schaardenburg, D., Reesink, H. W., Twisk, J. W. R., van de Stadt, R. J., van der Horst-Bruinsma, I. E., Gast, T. D., Habibuw, M. R., Vandenbroucke, J. P., & Dijkmans, B. A. C. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20431 · Cited by 176
Prognostic biomarkers in osteoarthritis
Attur, M. G., Krasnokutsky-Samuels, S., Samuels, J., & Abramson, S. B. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835a9381 · Cited by 175
A four‐gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis
Farina, G. A., Lafyatis, D., Lemaire, R., & Lafyatis, R. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27220 · Cited by 170
Altered miR-146a expression in Sjögren’s syndrome and its functional role in innate immunity
Pauley, K. M., Stewart, C. M., Gauna, A. E., Dupre, L. C., Kuklani, R., Chan, A. L., Pauley, B. A., Reeves, W. H., Chan, E. K. L., & Cha, S. (2011) · European Journal of Immunology · doi:10.1002/eji.201040757 · Cited by 169
The Acute-Phase Response in Relation to Radiographic Progression in Early Rheumatoid Arthritis: A Prospective Study During the First Three Years of the Disease
Leeuwen, M. A. V., van Rijswijk, M. H., van der Heijde, D. M. F. M., Meerman, G. J. T., van Riel, P. L. C. M., Houtman, P. M., van de Putte, L. B. A., & Limburg, P. C. (1993) · Lara D. Veeken · doi:10.1093/rheumatology/32.suppl_3.9 · Cited by 166
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Park, J. W., Kerbel, R. S., Kelloff, G. J., Barrett, J. C., Chabner, B. A., Parkinson, D. R., Peck, J. C., Ruddon, R. W., Sigman, C. C., & Slamon, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0785 · Cited by 158
Interferon Alpha as a Primary Pathogenic Factor in Human Lupus
Niewold, T. B. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0071 · Cited by 154
Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony‐stimulating factor
Rioja, I., Hughes, F. J., Sharp, C. H., Warnock, L. C., Montgomery, D. S., Akil, M., Wilson, A. G., Binks, M. H., & Dickson, M. C. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23667 · Cited by 138
IL-7 Promotes T H 1 Development and Serum IL-7 Predicts Clinical Response to Interferon-β in Multiple Sclerosis
Lee, L., Axtell, R. C., Tu, G. H., Logronio, K. A., Dilley, J., Yu, J., Rickert, M., Han, B., Evering, W., Walker, M. G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002400 · Cited by 118
Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
Hueber, W., Tomooka, B. H., Batliwalla, F., Li, W., Monach, P. A., Tibshirani, R. J., van Vollenhoven, R., Lampa, J., Saito, K., Tanaka, Y., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2706 · Cited by 118
Self-citation
Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: a systematic review and meta-analysis
Hoch, J. M., Mattacola, C. G., McKeon, J. M. M., Howard, J. S., & Lattermann, C. M. (2011) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2011.09.005 · Cited by 118
MicroRNAs in systemic rheumatic diseases
Ceribelli, A., Yao, B., Dominguez‐Gutierrez, P. R., Nahid, M. A., Satoh, M., & Chan, E. K. L. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3377 · Cited by 118
Molecular framework for response to imatinib mesylate in systemic sclerosis
Chung, L. S., Fiorentino, D. F., BenBarak, M. J., Adler, A. S., Mariano, M., Paniagua, R. T., Milano, A., Connolly, M. K., Ratiner, B. D., Wiskocil, R. L., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24221 · Cited by 116
Self-citation
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis
van Holten, J., Pavelká, K., Vencovský, J., Stahl, H., Rozman, B., Genovese, M. C., Kivitz, A. J., Alvaro, J., Nuki, G., Furst, D. E., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.020347 · Cited by 103
Multiplex assays for biomarker research and clinical application: Translational science coming of age
Fu, Q., Schoenhoff, F., Savage, W. J., Zhang, P., & Eyk, J. E. V. (2010) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200900217 · Cited by 99
A Plasmablast Biomarker for Nonresponse to Antibody Therapy to CD20 in Rheumatoid Arthritis
Owczarczyk, K. M., Lal, P. G., Abbas, A. R., Wolslegel, K., Holweg, C. T. J., Dummer, W., Kelman, A., Brunetta, P. G., Lewin‐Koh, N., Sorani, M. D., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002432 · Cited by 92
“Endogenous adjuvant” activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60
Kelly, K. M., Zhuang, H., Nacionales, D. C., Scumpia, P. O., Lyons, R., Akaogi, J., Lee, P. Y., Williams, B. R. G., Yamamoto, M., Akira, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21819 · Cited by 86
Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis
Eastman, P. S., Manning, W. C., Qureshi, F., Haney, D. J., Cavet, G., Alexander, C., & Hesterberg, L. K. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.06.003 · Cited by 84
The effects of interferon beta treatment on arthritis
Tak, P. P. (1999) · British journal of rheumatology · doi:10.1093/rheumatology/38.4.362 · Cited by 76
CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis
Rosengren, S., Wei, N., KALUNIAN, K. C., Kavanaugh, A., & Boyle, D. L. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq337 · Cited by 71
Insulin-Dependent Diabetes Mellitus and Autoimmunity: Islet-Cell Autoantibodies, Insulin Autoantibodies, and Beta-Cell Failure
Soeldner, J. S., Tuttleman, M., Srikanta, S., Ganda, O. P., & Eisenbarth, G. S. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510033131417 · Cited by 61
Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint
Meeuwisse, C. M., van der Linden, M. P. M., Rullmann, T., Allaart, C. F., Nelissen, R. G. H. H., Huizinga, T. W. J., Garritsen, A., Toes, R. E. M., van Schaik, R., & Mil, A. H. M. V. D. H. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30273 · Cited by 61
Human osteoblasts express functional CXC chemokine receptors 3 and 5: Activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and β‐N‐acetylhexosaminidase release
Lisignoli, G., Toneguzzi, S., Piacentini, A., Cattini, L., Lenti, A., Tschon, M., Cristino, S., Grassi, F., & Facchini, A. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10188 · Cited by 60
Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs
Bugatti, S., Manzo, A., Benaglio, F., Klersy, C., Vitolo, B., Todoerti, M., Sakellariou, G., Montecucco, C., & Caporali, R. F. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3742 · Cited by 54
The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis.
Chang, D. M., Weinblatt, M. E., & Schur, P. H. (1992) · PubMed · Cited by 53
Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab—preliminary data
Hama, M., Uehara, T., Takase, K., Ihata, A., Ueda, A., Takeno, M., Shizukuishi, K., Tateishi, U., & Ishigatsubo, Y. (2011) · Rheumatology International · doi:10.1007/s00296-011-1802-5 · Cited by 52
BCR-ABL Mutations in Chronic Myeloid Leukemia
Ernst, T., Rosée, P. G. L., Müller, M. C., & Hochhaus, A. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.005 · Cited by 48
Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases
Kasitanon, N., Petri, M., Haas, M., Magder, L. S., & Fine, D. M. (2007) · Lupus · doi:10.1177/0961203307085114 · Cited by 46
Metabolomic characterization of metabolic phenotypes in OA
Blanco, F. J., & Ruíz‐Romero, C. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.11 · Cited by 45
Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer
Sachdev, J. C., & Jahanzeb, M. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.07.001 · Cited by 37
Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs
Syversen, S. W., Haavardsholm, E. A., Bøyesen, P., Goll, G. L., Okkenhaug, C., Gaarder, P. I., van der Heijde, D. M. F. M., & Kvien, T. K. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.122325 · Cited by 36
Drug-free remission: is it already possible?
van den Broek, M., Huizinga, T. W. J., Dijkmans, B. A. C., & Allaart, C. F. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834563e3 · Cited by 30
Polymyalgia rheumatica and temporal arthritis.
Epperly, T. D., Moore, K. E., & Harrover, J. D. (2000) · PubMed · Cited by 25
Mechanism-derived gene expression signatures and predictive biomarkers in clinical oncology
Liu, E. T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500244102 · Cited by 23
Canakinumab for the treatment of cryopyrin-associated periodic syndromes
Walsh, G. M. (2009) · Drugs of today · doi:10.1358/dot.2009.45.10.1436882 · Cited by 17
Untitled work
(1999) · doi:10.1002/1529-0131(199901)42:1

Sorted by citations

Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00586 · Cited by 1,267
Allergen Immunotherapy in Children User’s Guide
Lozano, M. A., Akdiş, C. A., Akdiş, M., Alviani, C., Angier, E., Arasi, S., Arzt‐Gradwohl, L., Barber, D., Bazire, R., Cavkaytar, Ö., et al. (2020) · Pediatric Allergy and Immunology · doi:10.1111/pai.13189 · Cited by 382
Sequencing the functional antibody repertoire—diagnostic and therapeutic discovery
Robinson, W. H. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.220 · Cited by 178
Self-citation
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis
Giacomelli, R., Afeltra, A., Alunno, A., Bartoloni, E., Berardicurti, O., Bombardieri, M., Bortoluzzi, A., Caporali, R. F., Caso, F., Cervera, R., et al. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.08.003 · Cited by 142
Therapeutic target database update 2014: a resource for targeted therapeutics
Chu, Q., Zhang, C., Zhu, F., Xu, F., Chen, S. Y., Zhang, P., Li, Y., Yang, S. Y., Wei, Y., Tao, L., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1129 · Cited by 122

See all 109

Authors: Robinson, W. H., Lindstrom, T. M., Cheung, R. K., & Sokolove, J.
Affiliations: VA Palo Alto Health Care System (US)
Stanford Medicine (US)
Corresponding author: Robinson, William H.
ORCID: Robinson, William H.
Sokolove, Jeremy
Venue: Nature Reviews Rheumatology
Publisher: Springer Science and Business Media LLC
Published: 2013-02-19
Volume: 9
Issue: 5
Pages: 267-276
ISSN: 1759-4790 (ISSN-L)
1759-4804
DOI: 10.1038/nrrheum.2013.14
PMC: PMC3673766
OpenAlex: W2010417263
Cited by: 109
References: 107
Citations by year: 2026: 5 · 2025: 10 · 2024: 4 · 2023: 7 · 2022: 5 · 2021: 8 · 2020: 12 · 2019: 9 · 2018: 5 · 2017: 12 · 2016: 7 · 2015: 9 · 2014: 11 · 2013: 5
FWCI: 1.73
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Rheumatology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Heart, Lung, and Blood Institute (N01-HV 00242)
National Institute of Allergy and Infectious Diseases (U01 U01AI101981, U01AI101981)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (RC1AR058713, R01AR054822)
Topics: Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Keywords: mechanistic biomarkers, actionable biomarkers, rheumatic diseases, clinical decision-making, disease activity, drug development, early diagnosis, treatment response prediction, pathogenesis, clinical trial recruitment
MeSH terms: Animals, Decision Making, Humans, Rheumatic Diseases, Rheumatology, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mechanistic biomarkers for clinical decision making in rheumatic diseases

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks